Business Standard

Strong US portfolio boost for Lupin

Market share gains in the US led to higher operating or underlying profit

Lupin Pharma
Premium

Ujjval Jauhari
Lupin's performance in December quarter was ahead of Street estimates. Buoyed by growth across geographies, sales grew 32 per cent to Rs 4,405 crore over a year ago, ahead of Bloomberg consensus estimate of Rs 4,293 crore. Operating or underlying profit was even more impressive at Rs 1,215.8 crore, up 43.6 per cent year over year, and way ahead of Rs 1,061.4-crore estimate. The operating margin at 27.6 per cent grew 230 basis points year over year. Despite higher taxes, net profit saw 20.7 per cent growth to Rs 619 crore. 

Profit growth was largely a function of its performance in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in